[Efficacy and safety assessment of neoadjuvant paclitaxel and trastuzumab in Chinese women with Her-2 positive operable breast cancer].

Zhonghua zhong liu za zhi [Chinese journal of oncology]

Volumn 32, Issue 7, 2010, Pages 544-547

  Liao, Ning ^a   Zhang, Guo chun ^b   Li, Xue rui ^b   Yao, Meng ^b   Wang, Kun ^b   Zu, Jian ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ARTICLE; ASIAN; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; NEUTROPENIA; PAGET NIPPLE DISEASE; PATHOLOGY; PHASE 2 CLINICAL TRIAL; REMISSION;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPENIA; PACLITAXEL; RECEPTOR, ERBB-2; REMISSION INDUCTION;

EID: 79957955010     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)